A Clinical and Budgetary Impact Analysis of Introducing Sugammadex for Routine Reversal of Neuromuscular Blockade in a Hypothetical Cohort in the US
Crossref DOI link: https://doi.org/10.1007/s12325-021-01701-1
Published Online: 2021-04-19
Published Print: 2021-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Jiang, Yiling
Bash, Lori D.
Saager, Leif
Funding for this research was provided by:
Merck Sharp and Dohme
Text and Data Mining valid from 2021-04-19
Version of Record valid from 2021-04-19
Article History
Received: 10 December 2020
Accepted: 10 March 2021
First Online: 19 April 2021